CytomX Therapeutics, Inc. (CTMX)

From the record

CytomX Therapeutics, Inc.'s filings since 2017 show 3 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2025-02-26); a warning not to rely on past financial statements (8-K item 4.02, the latest 2023-02-24); an auditor change (8-K item 4.01, the latest 2017-07-17) (its current reports).

From the record

CytomX Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $15 million in fiscal 2016 to $76 million in fiscal 2025, up 19.8% a year; it rose in 5 of 9 years; the deepest fall was 62% from fiscal 2017 to fiscal 2019; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, CytomX Therapeutics, Inc.'s diluted share count grew about 28.0% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 7 sales (3 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-16 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, CytomX Therapeutics, Inc. lost about 18 cents for every dollar of shareholders' money. Leverage: it owed about 35 cents per dollar of assets, and net share issuance: its share count grew 62.8% over the year (the filed statements).

From the record

CytomX Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $76 million in fiscal 2025 ranks in the top 37% by size; a net margin of -22.8% ranks in the top 33%; revenue growth of 12.7% a year over the last 3 filed years ranks in the top 45% (its annual reports).

From the record

CytomX Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mccarthy, Sean A. (CEO, as filed), filing under that title since 2015-10-07, 11.1 years (top 14% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 5.5 years (bottom 47%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 45%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

CytomX Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $13 million against no long-term debt tagged leaves 8.4% of its assets as net cash, bottom 23% of its family; cash from operations less capital spending is -99.5% of revenue (bottom 50%); research spending of 90.2% of revenue (bottom 48%) (its annual report).

From the record

CytomX Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 12.7% a year over the last three filed years against 19.8% over all 10, slowing (bottom 41% of its family); the newest year grew -44.8% (bottom 19%); research spending grew -14.9% a year (bottom 24%); capital spending grew -49.8% a year (bottom 21%) (its annual reports). CytomX Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

CytomX Therapeutics, Inc.'s newest year against its own record: revenue of $76 million in fiscal 2025 came in 65.8% below the $223 million its prior three years' pace pointed to (bottom 14% of its family); net income of $17 million against a prior three-year average of $23 million (top 46%); a net margin of -22.8% against -54.8% before (top 41%) (its annual reports).